Alternative names (23)
clinical trial • clinical trial phase • clinicalTest • clinicalTestAvailable • clinicalTesting • clinicalTrial • clinicalTrialIdentifier • clinicalTrialIndication • clinicalTrialLocation • clinicalTrialName • clinicalTrialPhase3 • clinicalTrialStatus • clinicalTrialTarget • clinicalTrials • clinicalTrialsGovID • clinicalTrialsPhase • countryOfClinicalTrial • has clinical trial phase • hasClinicalTrial • hasClinicalTrialPhase • hasClinicalTrials • notableClinicalTrial • trialDesign • moreRandom triples
| Subject | Object |
|---|---|
| gptkb:tirzepatide | gptkb:SURPASS-5 |
| gptkb:tabalumab | rheumatoid arthritis |
| gptkb:T_Cell_Therapy | II |
| gptkb:batoclimab | Phase 3 (as of 2024) |
| gptkb:PACIFIC_trial | NCT02125461 |
| gptkb:NTLA-2001 | Phase 1 |
| gptkb:Fractyl_Health | Revita-2 |
| gptkb:Noctura_400 | conducted in the UK |
| gptkb:VTC-21 | Phase 1 |
| gptkb:Optic_Nerve | gptkb:Visual_field_test |
| gptkb:Aeson_artificial_heart | gptkb:Denmark |
| gptkb:Tislelizumab | ongoing |
| gptkb:IMR-687 | Phase 2 |
| gptkb:Alvocidib | Phase II |
| gptkb:SYNB1934 | Phase 2 |
| gptkb:DESCARTES_trial | Phase 3 |
| gptkb:Bravemind_VR_system | multiple published studies |
| gptkb:GW501516 | terminated due to safety concerns |
| gptkb:PLX4032 | Phase III |
| gptkb:BIRB796 | Phase II |